» Articles » PMID: 38164579

[F]FDG PET/CT-Avid Discordant Volume As a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study

Abstract

[F]FDG PET/CT and [Ga]Ga-DOTATATE PET/CT are both used to predict tumor biology in neuroendocrine neoplasms. Although the presence of discordant ([F]FDG-avid/non-[Ga]Ga-DOTATATE-avid) disease predicts poor prognosis, the significance of the volume of such discordant disease remains undetermined. The aim of this study is to investigate discordant tumor volume as a potential biomarker in patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEPNENs). A multicenter retrospective study in patients with advanced GEPNENs and paired [F]FDG and [Ga]Ga-DOTATATE PET/CT no more than 85 d apart was conducted. Patients with discordant disease were identified by the NETPET score, and discordant lesions were contoured with a flat [F]FDG SUV cutoff of 4. The primary variable of interest was the total discordant volume (TDV), which was the sum of the volumes of discordant lesions. Patients were dichotomized into high- and low-TDV cohorts by the median value. The primary endpoint was overall survival. In total, 44 patients were included (50% men; median age, 60 y), with primary cancers in the pancreas (45%), small bowel (23%), colon (20%), and other (12%). Of the patients, 5% had grade 1 disease, 48% had grade 2 disease, and 48% had grade 3 disease (24% well differentiated, 67% poorly differentiated, 10% unknown within the grade 3 cohort). The overall median survival was 14.1 mo. Overall survival was longer in the low-TDV cohort than in the high-TDV cohort (median volume, 43.7 cm; survival time, 23.8 mo vs. 9.4 mo; hazard ratio, 0.466 [95% CI, 0.229-0.948]; = 0.0221). Patients with no more than 2 discordant intrahepatic lesions survived longer than those with 2 or more lesions (31.8 mo vs. 10.2 mo, respectively; hazard ratio, 0.389 [95% CI, 0.194-0.779]; = 0.0049). TDV is a potential prognostic biomarker in GEPNENs and should be investigated in future neuroendocrine neoplasm trials.

Citing Articles

[F]FDG and [Ga]Ga-FAPI-04 Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms.

Michalski K, Kosmala A, Hartrampf P, Heinrich M, Serfling S, Schlotelburg W J Nucl Med. 2024; 65(12):1899-1903.

PMID: 39477500 PMC: 11619591. DOI: 10.2967/jnumed.124.268288.


Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient.

Pacak K, Taieb D, Lin F, Jha A J Clin Endocrinol Metab. 2024; 109(9):2366-2388.

PMID: 38652045 PMC: 11319006. DOI: 10.1210/clinem/dgae252.


Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.

Di Franco M, Zanoni L, Fortunati E, Fanti S, Ambrosini V Curr Oncol Rep. 2024; 26(5):538-550.

PMID: 38581469 PMC: 11063107. DOI: 10.1007/s11912-024-01526-5.

References
1.
Sorbye H, Welin S, Langer S, Vestermark L, Holt N, Osterlund P . Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2012; 24(1):152-60. DOI: 10.1093/annonc/mds276. View

2.
Karfis I, Marin G, Levillain H, Drisis S, Muteganya R, Critchi G . Prognostic value of a three-scale grading system based on combining molecular imaging with Ga-DOTATATE and F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias. Oncotarget. 2020; 11(6):589-599. PMC: 7021233. DOI: 10.18632/oncotarget.27460. View

3.
Chan D, Bernard E, Schembri G, Roach P, Johnson M, Pavlakis N . High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms. Neuroendocrinology. 2019; 110(11-12):950-958. DOI: 10.1159/000504673. View

4.
Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A . 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010; 16(3):978-85. DOI: 10.1158/1078-0432.CCR-09-1759. View

5.
Stokmo H, Aly M, Bowitz Lothe I, Borja A, Seraj S, Ghorpade R . Volumetric parameters from [ F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. J Neuroendocrinol. 2022; 34(7):e13170. PMC: 9539477. DOI: 10.1111/jne.13170. View